BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00024115
First received: September 13, 2001
Last updated: January 11, 2007
Last verified: December 2006

September 13, 2001
January 11, 2007
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00024115 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Phase I Study of Recombinant BL22 Immunotoxin in Patients With CD22-Positive B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

RATIONALE: The BL22 immunotoxin can locate tumor cells and kill them without harming normal cells.

PURPOSE: Phase I trial to study the effectiveness of the BL22 immunotoxin in treating patients who have non-Hodgkin's lymphoma or chronic lymphocytic leukemia.

OBJECTIVES:

  • Determine the toxicity and therapeutic efficacy of recombinant BL22 immunotoxin in patients with CD22-positive B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukemia.
  • Determine the pharmacokinetics, including the terminal elimination serum half-life area under the curve and volume of distribution, of recombinant BL22 immunotoxin in these patients.
  • Determine the immunogenicity of recombinant BL22 immunotoxin in these patients.
  • Determine the effect of recombinant BL22 immunotoxin on various components of the circulating cellular immune system in these patients.

OUTLINE: This is a dose-escalation study.

Patients receive recombinant BL22 immunotoxin IV over 30 minutes on days 1, 3, and 5. Patients may be retreated at least every 20 days for up to 25 courses in the absence of disease progression and sufficient neutralizing antibodies.

Cohorts of 3-6 patients receive escalating doses of recombinant BL22 immunotoxin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.

PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within 2 years.

Interventional
Phase 1
Primary Purpose: Treatment
  • Leukemia
  • Lymphoma
  • Drug: BL22 immunotoxin
  • Procedure: antibody therapy
  • Procedure: biological response modifier therapy
  • Procedure: immunotoxin therapy
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
Not Provided
Not Provided
Not Provided

DISEASE CHARACTERISTICS:

  • Histologically confirmed chronic lymphocytic leukemia or prolymphocytic leukemia:
  • Failed prior standard chemotherapy and treatment is medically indicated as evidenced by the following:
  • Progressive disease-related symptoms
  • Progressive cytopenias due to marrow involvement
  • Progressive or painful splenomegaly or adenopathy
  • Rapidly increasing lymphocytosis
  • Autoimmune hemolytic anemia or thrombocytopenia
  • Increased frequency of infections OR
  • Confirmed CD22+ B-cell indolent non-Hodgkin's lymphoma
  • Stages II-IV that have failed at least 1 prior standard therapy and treatment is medically indicated
  • No patients whose serum neutralizes BL22 or PE38 in tissue culture, due to antitoxin or antimouse-IgG antibodies
  • No central nervous system disease requiring treatment
  • If the patient is non-leukemic, the absolute neutrophil count must be greater than 1,000/mm3 and the platelet count greater than 40,000/mm3

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • Karnofsky 60-100%

Life expectancy:

  • More than 6 months

Hematopoietic:

  • See Disease Characteristics

Hepatic:

  • ALT and AST less than 5 times upper limit of normal

Renal:

  • Adequate renal function

Pulmonary:

  • Adequate pulmonary function

Other:

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • HIV negative

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Prior bone marrow transplantation allowed
  • At least 3 weeks since prior interferon for malignancy

Chemotherapy:

  • See Disease Characteristics
  • At least 3 weeks since prior cytotoxic chemotherapy for malignancy

Endocrine therapy:

  • Not specified

Radiotherapy:

  • At least 3 weeks since prior radiotherapy for malignancy

Surgery:

  • Not specified

Other:

  • At least 3 weeks since prior retinoids
  • At least 3 weeks since prior systemic therapy for cancer
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00024115
CDR0000068892, NCI-01-C-0213, NCI-5336
Not Provided
Not Provided
National Cancer Institute (NCI)
Not Provided
Study Chair: Robert Kreitman, MD National Cancer Institute (NCI)
National Cancer Institute (NCI)
December 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP